Teriparatide
Also known as: PTH(1-34) · rhPTH(1-34)
The N-terminal 34 residues of human parathyroid hormone, an approved anabolic osteoporosis medicine and a clean illustration of dose-schedule dependence in pharmacology.
Development status: Approved as a medicine in one or more jurisdictions
Identifiers and molecular characteristics
- CAS number
- Not verified
- Molecular formula
- Not verified
- Molecular mass
- Not verified
- Amino-acid sequence
- Not verified
- PubChem CID
- Not verified
Identifiers are published only with a source and a check date. Fields marked “not verified” have not yet been confirmed against a primary source — we show the gap rather than an unchecked figure. Always confirm against the certificate of analysis for the specific lot you hold.
Biological targets
- PTH1 receptor
Mechanism of action
Intermittent PTH1 receptor stimulation favours bone formation, whereas continuous exposure favours resorption. The therapeutic effect depends entirely on intermittent administration — the same molecule produces opposite skeletal outcomes under different schedules.
Research evidence and its limits
Phase 3 fracture-endpoint trials and extensive post-approval use.
Safety considerations
Where this compound is an approved medicine, the authoritative safety source is the product labelling issued by the relevant regulator — not this page. Research-grade material is not pharmaceutical product and carries none of those assurances. Supplied and discussed here strictly as a laboratory research material. Not a medicine, not for human or veterinary administration, and nothing on this page should be read as a dosing, treatment or safety recommendation.
Analytical identification and quality testing
Identity by high-resolution mass spectrometry against the expected mass, purity by RP-HPLC with UV detection. Tandem MS sequencing or peptide mapping gives stronger identity evidence than mass alone.
Regulatory status
Approved in many jurisdictions for osteoporosis.
Frequently asked questions
How can the same hormone both build and break down bone?
Schedule. Intermittent exposure favours osteoblast activity and net formation; continuous elevation, as in hyperparathyroidism, favours resorption. It is one of the clearest examples of dosing schedule determining direction of effect.
References
Related compounds
Entry last reviewed 2026-10-11. Regulatory status and scientific understanding change; verify against primary sources before relying on anything here.